Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 139Vincristine 105Rituximab 100Doxorubicin 87Etoposide 79Prednisone 69Cytarabine 67Filgrastim 63Specimen Handling 62Methotrexate 60Biopsy 60Magnetic Resonance Spectroscopy 51fludarabine phosphate 50Dexamethasone 47Radiotherapy 43Peripheral Blood Stem Cell Transplantation 35Leucovorin 35Bortezomib 32Prednisolone 28Mercaptopurine 27merphos 24Ifosfamide 24Asparaginase 24Daunorubicin 23Lenalidomide 22ibrutinib 21fludarabine 21Calcium Dobesilate 21pegaspargase 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anti-Bacterial Agents × Lymphoid × Clear all
NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
19 enrolled 18 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡